Janux Therapeutics (JANX)

• Market cap: $1.67B
• 1 day: -6.55%
• 5 days: 5.58%
• 1 month: 17.34%
• 3 months: 15.06%
• 6 months: -14.56%
• Year to date: -47.76%
• 1 year: -48.7%
• 5 years: 10.58%
• 10 years: 10.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Employees: 103